Autolus Therapeutics plc (AUTL)
About Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $75.4M
- Net income
- -$287.5M
- Total assets
- $589.1M
- Market cap
- $407.2M
- Gross margin
- -27.8%
- Operating margin
- -358.9%
- Net margin
- -381.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $75.4M
- Cost of revenue
- $96.4M
- Gross profit
- -$21.0M
- Operating expenses
- $249.6M
- Operating income
- -$270.5M
- Income tax
- $2.0M
- Net income
- -$287.5M
- EPS (basic)
- $-1.08
- EPS (diluted)
- $-1.08
Balance sheet
- Total assets
- $589.1M
- Current assets
- $435.9M
- Total liabilities
- $410.9M
- Current liabilities
- $73.4M
- Shareholders’ equity
- $178.1M
Cash flow
- Operating cash flow
- -$283.6M
- Investing cash flow
- $158.5M
- Financing cash flow
- -$4.3M
- Net cash flow
- -$123.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $407.2M
- EPS (diluted)
- $-1.08
- Shares outstanding
- 282.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 22, 2018
Autolus Therapeutics plc (AUTL) Stock Price
- Reported a net loss of $287.5M in FY2025.
- Gross margin of -27.8%, net margin -381.4%.
- Trading 46% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Autolus Therapeutics plc.
Write a review
News about Autolus Therapeutics plc
News & sentiment via Polygon.io
Autolus Therapeutics plc: frequently asked questions
Is Autolus Therapeutics plc an American company?
Autolus Therapeutics plc is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Autolus Therapeutics plc publicly traded?
Yes — Autolus Therapeutics plc is a publicly traded company. Its stock trades under the ticker symbol AUTL on the NASDAQ.
What does Autolus Therapeutics plc do?
Autolus Therapeutics plc is an American Pharmaceuticals company in the Health & Beauty sector.
When was Autolus Therapeutics plc founded?
Autolus Therapeutics plc was founded in 2014.
